Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes

Hepatology

Volumn 60, Issue 6, 2014, Pages 2008-2016

  Zhang, Xiaodan ^a   Harmsen, William S ^b   Mettler, Teresa A ^a   Kim, W Ray ^a   Roberts, Rosebud O ^c   Therneau, Terry M ^b   Roberts, Lewis R ^a   Chaiteerakij, Roongruedee ^a,d  

^a MAYO CLINIC   (United States)

^b Mayo Clinic College of Medicine   (United States)

^c MAYO CLINIC CANCER CENTER   (United States)

^d KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CREATININE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; SERUM ALBUMIN; ANTIDIABETIC AGENT;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CHILD PUGH SCORE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC PATIENT; DIARRHEA; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN TREATMENT; LACTIC ACIDOSIS; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PH; PORTAL HYPERTENSION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; COMPLICATION; EPIDEMIOLOGY; MIDDLE AGED; MORTALITY; UNITED STATES;

AGED; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIVER CIRRHOSIS; MALE; METFORMIN; MIDDLE AGED; MINNESOTA; RETROSPECTIVE STUDIES;

EID: 84911999849     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27199     Document Type: Article

References (28)

1. Miniño AM, Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2008. Natl Vital Stat Rep 2011;59:1-126.
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-2128.
3. Wlazlo N, Beijers HJ, Schoon EJ, Sauerwein HP, Stehouwer CD, Bravenboer B. High prevalence of diabetes mellitus in patients with liver cirrhosis. Diabet Med 2010;27:1308-1311.
4. Wlazlo N, van Greevenbroek M, Curvers J, Schoon EJ, Friederich P, Twisk J, et al. Diabetes mellitus at the time of diagnosis of cirrhosis is associated with higher incidence of spontaneous bacterial peritonitis, but not with increased mortality. Clin Sci 2013;125:341-348.
5. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460-468.
6. El-Serag HB, Everhart JE. Diabetes increases the risk of acute hepatic failure. Gastroenterology 2002;122:1822-1828.
7. Butt Z, Jadoon NA, Salaria ON, Mushtaq K, Riaz IB, Shahzad A, et al. Diabetes mellitus and decompensated cirrhosis: risk of hepatic encephalopathy in different age groups. J Diabetes 2013;5:449-455.
8. Veldt BJ, Chen W, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008;47:1856-1862.
9. Quintana JO, Garcia-Compean D, Gonzalez JA, Perez JZ, Gonzalez FJ, Espinosa LE, et al. The impact of diabetes mellitus in mortality of patients with compensated liver cirrhosis-a prospective study. Ann Hepatol 2011;10:56-62.
10. de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 1999;22:756-761.
11. Bo S, Benso A, Durazzo M, Ghigo E. Does use of metformin protect against cancer in type 2 diabetes mellitus? J Endocrinol Invest 2012;35:231-235.
12. Chaiteerakij R, Yang JD, Harmsen WS, Slettedahl SW, Mettler TA, Fredericksen ZS, et al. Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology 2013;57:648-655.
13. Chen HP, Shieh JJ, Chang CC, Chen TT, Lin JT, Wu MS, et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 2013;62:606-615.
14. Donadon V, Balbi M, Mas MD, Casarin P, Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 2010;30:750-758.
15. Nkontchou G, Cosson E, Aout M, Mahmoudi A, Bourcier V, Charif I, et al. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab 2011;96:2601-2608.
16. Adams LA, Harmsen S, St Sauver JL, Charatcharoenwitthaya P, Enders FB, Therneau T, et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol 2010;105:1567-1573.
17. Kita Y, Takamura T, Misu H, Ota T, Kurita S, Takeshita Y, et al. Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis. PloS One 2012;7:e43056.
18. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1082-1090.
19. Garinis GA, Fruci B, Mazza A, De Siena M, Abenavoli S, Gulletta E, et al. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int J Obes 2010;34:1255-1264.
20. Brackett CC. Clarifying metformin's role and risks in liver dysfunction. J Am Pharm Assoc 2010;50:407-410.
21. Brown JB, Pedula K, Barzilay J, Herson MK, Latare P. Lactic acidosis rates in type 2 diabetes. Diabetes Care 1998;21:1659-1663.
22. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010;(4):CD002967.
23. Chan NN, Brain HP, Feher MD. Metformin-associated lactic acidosis: a rare or very rare clinical entity? Diab Med 1999;16:273-281.
24. Edwards CM, Barton MA, Snook J, David M, Mak VH, Chowdhury TA. Metformin-associated lactic acidosis in a patient with liver disease. QJM 2003;96:315-316.
25. Renda F, Mura P, Finco G, Ferrazin F, Pani L, Landoni G. Metformin-associated lactic acidosis requiring hospitalization. A national 10 year survey and a systematic literature review. Eur Rev Med Pharmacol Sci 2013;17(Suppl 1):45-49.
26. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998;338:265-266.
27. Kamber N, Davis WA, Bruce DG, Davis TM. Metformin and lactic acidosis in an Australian community setting: the Fremantle Diabetes Study. Med J Aust 2008;188:446-449.
28. Seidowsky A, Nseir S, Houdret N, Fourrier F. Metformin-associated lactic acidosis: a rognostic and therapeutic study. Crit Care Med 2009;37:2191-2196.